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SIGNIFICANCE
Although recent developments have revolutionized melanoma care, most patients still die of their disease. To improve melanoma outcomes further, we developed a powerful precision medicine platform to monitor patient responses, and to identify and validate hypothesis-driven therapies for patients who do not respond, or who develop resistance to current treatments. 
INTRODUCTION
Malignant melanoma is the most deadly skin cancer and each year, there are over 76,000 melanoma cases and 9,000 deaths in the US (1) over 100,000 cases and 22,000 deaths in Europe (2) . A paradigm shift has occurred in melanoma treatment in the last 5 years. Improved understanding of the genetic landscape of melanoma has facilitated development of effective targeted therapies and improved knowledge of the molecular controls of the immune system has driven the development of immune checkpoint inhibitors. However, not all patients benefit from these treatments and resistance is a persistent problem.
The BRAF oncogene is mutated in ~50% of melanomas and although BRAF and MEK inhibitors increase survival in these patients (3) (4) (5) , even when combined, most patients develop resistance after 6-12 months (6) (7) (8) . Antibody antagonists of CTLA-4 and PD-1 provide survival benefits in a subset of patients (9) (10) (11) and even better responses when combined (10, 11) . However, it is unclear which patients will benefit from these agents, so identification of biomarkers of response is a priority (12, 13) . Moreover, most patients derive little benefit from CTLA-4 immune checkpoint inhibitors after BRAF inhibitors (14) and resistance to targeted therapies is driven by several mechanisms (9) . Currently there are no guidelines or biomarkers to assist selection of second-line therapies, so selecting follow-up treatments for patients is challenging. One option is to continue treatment beyond progression (15) , but it is unclear which patients will benefit. Furthermore, melanoma patients lacking a BRAF mutation have fewer therapeutic options and are currently limited to chemotherapy or immunotherapy, so additional treatment options are needed for these patients. capacity to characterize comprehensively the genetic alterations and pathways in tumors, raising the possibility of developing therapies based on the genetic make up of each tumor (16) . The Genomics of Drug Sensitivity in Cancer Project at the Sanger Institute is an example of a large-scale drug screen, that incorporates genomic and gene expression data to identify drug response biomarkers that could inform optimal application of cancer drugs (17, 18) .
In melanoma acquired resistance to systemic treatment appears to be driven by clonal evolution and selection of resistant tumor cells (19) . Repeated biopsies to study genomic alterations resulting from therapies are invasive, can be difficult to obtain and may be confounded by intratumoral heterogeneity. A possible resolution to this problem is analysis of circulating tumor DNA (ctDNA) released by cancer cells into the plasma (20) . Serial analysis of ctDNA can be used to track genomic evolution of metastatic cancers in response to therapy to complement invasive biopsy approaches and identify mutations associated with acquired drug resistance in advanced cancers (21), but it is unclear how this technology can be used in the routine setting of a hospital. Patient-derived xenografts (PDX) also have the potential to assist personalized medicine decisions (22), but their development requires access to tumor tissue that is often inaccessible or only accessible by invasive biopsies. One solution to this challenge is to develop xenografts from circulating tumor cells (CTCs), so-called CTC-derived xenografts (CDXs), recently developed for small cell lung cancer (SCLC) (23) but not yet for melanoma.
We have developed a platform of technologies for personalized medicine in melanoma patients by exploiting technical advances in sequencing and xenografts to monitor responses to treatment and explore new treatment options and describe results from our collection of 364 samples from 214 advanced melanoma patients. 
RESULTS
Circulating tumor DNA reveals patient responses to treatment
We collected plasma samples from 101 melanoma patients being treated as part of clinical trials or receiving current standards of clinical care to determine if ctDNA analysis can be used to support clinical diagnostics. The patients presented stage II, III or IV cutaneous, acral, mucosal or uveal melanoma, were 26 to 89 years old and received treatments including chemotherapy, targeted therapies and immunotherapy ( Fig. 1A ; Supplementary Table S1 ). Most patients are still alive and in some cases have been followed for over a year ( Fig. 1A ; Supplementary Table   S1 ).
Our initial studies were retrospective, as in patient 1 who presented BRAF V600E metastatic melanoma with spread to the lymph nodes and lung (Fig. 1B) .
The patient presented a partial response to dabrafenib/trametinib, but relapsed at ~23 weeks (Fig. 1B) . Accordingly, the BRAF V600E ctDNA levels initially fell with tumor shrinkage, but increased again on relapse (Fig. 1B) . The patient did not respond to ipilimumab and this was also reflected in the BRAF V600E ctDNA levels. Note that serum lactate dehydrogenase (LDH) did not reflect tumor responses (Fig. 1B) .
Finally, WES of the patient's resistant tumor revealed an NRAS Q61R mutation ( Supplementary Fig. S1 ) that could be detected retrospectively in the patient's ctDNA from week 25 (Fig. 1B) .
We also performed prospective studies. Patient 2 presented rapidly progressing metastatic BRAF V600R melanoma in liver, hepatic and peritoneal lymph nodes (Fig. 1C) . Ipilimumab was ineffective, but there was a dramatic response to dabrafenib/trametinib, with tumor shrinkage in multiple lesions (Fig. 1C) CT scan, and the response to dabrafenib/trametinib six weeks before the CT scan, whereas serum LDH failed to predict these responses (Fig. 1C) .
Another example of ctDNA predicting clinical response was seen with patient 3, who presented metastatic BRAF V600E melanoma in lymph nodes and lung. After one cycle of ipilimumab, treatment was halted due to toxicities that needed to be managed by immunosuppression, allowing a second cycle of ipilimumab at week 5.
BRAF
V600E ctDNA at 3 and 5 weeks predicted an exceptional response, confirmed by CT scan at week 8 (Fig. 1D) We also investigated if WES of ctDNA could reveal mechanisms of resistance to therapy. Our first studies were retrospective as in patient 5 who was previously treated with lymphadenectomy for stage III disease and re-presented with isolated metastatic disease in the lung and was treated by pneumonectomy ( Fig.   2A ). Seventeen weeks later new subcutaneous, liver and brain metastases developed that initially responded to vemurafenib, but then relapsed during the period from weeks 18 to 40. Following a short-lived clinical response to dabrafenib/trametinib, treatment was halted at week 50 and the patient died at week 54. The BRAF V600E ctDNA was predictive of the initial response, protracted relapse to vemurafenib, and the short-lived response to dabrafenib/trametinib, whereas serum LDH only predicted the late-stage relapse to dabrafenib/trametinib ( Fig. 2A) .
To determine the mechanism of resistance to vemurafenib, we performed WES of the ctDNA sample at week 50. This revealed an NRAS Q61K mutation (Fig. 2B ) that was not present at baseline, but emerged at the onset of resistance at week 26 ( Fig.   2A ).
For routine monitoring of common mechanisms of resistance, we developed a targeted sequencing panel of ten loci known to mediate resistance to BRAF and MEK inhibitors, using a multiplexed PCR reaction to enrich target DNA regions (Fig.   2C and Supplementary Table S2 ). Patient 6 presented with stage IV disease with brain, lung, and omentum metastases. Vemurafenib and dabrafenib/trametinib were administered with brief interruptions to sustain BRAF/MEK inhibition while managing toxicities (Fig. 2D) confirmed at week 28 (Fig. 2D, Supplementary Fig. S2A ). Targeted sequencing of the ctDNA revealed a de novo PIK3CA E545K mutation that emerged coincident with resistance to dabrafenib at week 32 ( Fig. 2D ) when treatment was withdrawn, followed by death at week 36.
Finally, patient 7 presented aggressive disease with multiple subcutaneous, liver and bone metastases, abdominal lymphadenopathy, pelvic mass and peritoneal thickening (Fig. 2E) nodes, and visceral metastases, and we also established PDXs from pleural effusions, ascites and a primary uveal melanoma from an enucleated eye (Fig. 3A) .
The patients were all stage III or IV, but many stage III patients progressed to stage IV over the course of study (Fig. 3A) . They ranged from 25 to 95 years and they were treatment naïve or had received typical treatments, including chemotherapy, targeted therapy and immunotherapy (Fig. 3A) . Our success rate for PDX engraftment was 72% with median latency to 100mm 3 of 49 days, and as many patients were followed for up to 12 months (Fig. 3A , Supplementary We exemplify our approach with patient 5, for whom we developed a PDX from the pneumonectomy previously described ( analogue with superior oral bioavailability in mice (25, 26). In parallel with the patient, the mice initially responded, but complete regression was not achieved and resistance emerged after 12-16 weeks ( Fig. 3E and Supplementary Fig. S3 ). The patient was judged unlikely to benefit from ipilimumab, radiotherapy or surgery and WES did not reveal new actionable therapeutic targets in the resistant PDX (data not shown), leaving dabrafenib plus trametinib as the patient's only treatment option.
The preferred treatment option was a combination of dabrafenib and trametinib, though it was understood that any benefit would be short lived (27 UK, but the patient was ineligible for this program due to the brain lesions. However, we found that the PLX4720-resistant PDX responded briefly (~10 weeks) to dabrafenib/trametinib (Fig. 3F) , and used this data to obtain permission from the sponsor for this combination in the patient. As in the mice, the patient received a brief (8 week) clinical benefit from the combination, showing that PDX technology can be used to refine patient care.
BRAF inhibitor treatment past progression induces growth and metastasis in a drug-resistant tumor
Clinicians currently face a difficult decision as to whether to continue to treat beyond progression patients who relapse on targeted therapy with the hope of slowing tumor growth, or whether to halt targeted therapy and consider alternatives.
We illustrate this problem in patient 8 who developed inoperable axillary nodal disease that carried a BRAF V600E mutation. The patient received vemurafenib and after 12 weeks a 50% reduction in tumor volume enabled complete resection of the lesion (Fig. 3G) . Vemurafenib was not provided post surgery due to a lack of evidence for benefit from adjuvant therapy, but the patient relapsed with metastatic disease and although vemurafenib was re-administered at week 24, the disease progressed rapidly and the patient died at week 37 ( Fig. 3G ).
We established two PDXs from this patient, one from the tumor removed at week 12 and one from a pleural effusion drained at week 37 ( revealed an NRAS Q61K mutation that was not present in the biopsy taken at presentation ( Fig. 3J ) and this mutation was further enriched in the 37-week pleural effusion PDX (Fig. 3K) . Thus, consistent with our previous cell line studies (28, 29) BRAF inhibition accelerated the growth and metastasis in this NRAS mutant PDX, suggesting that treatment beyond progression was inappropriate for the patient and highlighting how improved knowledge of melanoma biology could assist with decisions about when to continue and when to withdraw treatment.
Identification and validation of treatments for non-V600 mutant BRAF patients
Current treatments for non-V600 mutant BRAF patients are based on immunotherapy and chemotherapy but ~50% of patients do not respond. A key challenge for personalized medicine is therefore to develop treatments for these patients, so we tested if this could be achieved by combining next generation sequencing and PDX technologies. We sequenced 80 patient tumors by WES or by targeted sequencing with a panel of 40 melanoma driver genes and genes known to be drivers of resistance to targeted therapy (Supplementary Table S4 ) (30-32).
Forty-eight tumors carried V600 BRAF mutations and one a K601 mutation ( We were intrigued by patient 9 ( kinase-dead BRAF mutation (G466E), a rare oncogenic HRAS mutation (G13V) (Fig.   4C ), and a loss-of-function RB1 mutation, also rare in melanoma. This unusual constellation of mutations is a therapeutic challenge, because oncogenic RAS drives paradoxical activation of kinase-dead BRAF, so despite the BRAF mutation, BRAF inhibitors will be ineffective (28, 34). The patient originally presented with primary melanoma on the forearm with synchronous regional nodal metastases and was rendered disease-free by surgery, but relapsed after 36 weeks (Fig. 4B ). Two cycles of DTIC and one dose of ipilimumab were administered, but a rapidly worsening condition and poor performance status prevented further treatment.
We hypothesized that MEK inhibitors may be effective in this tumor and it is reported that cells lacking RB1 are sensitive to paclitaxel (35) (Fig. 4D, 4E ), so we tested these drugs in a PDX from the patient's metastatic lesion ( CTCs into NSG mice (Fig. 5B) . We have been successful in 7 cases, failed in 14 and continue to follow 26 ( Fig. 5A ) which represents a current success rate of 15%.
A CDX was generated for patient 10, who presented highly aggressive widespread BRAF V600E melanoma that was unresponsive to targeted therapy ( ) and 2 months after excision of the primary tumor, macroscopic metastases were seen in the liver, lungs, kidneys, lymph nodes, brain and distant subcutaneous tissue ( Fig. 5F-G) , and we confirmed that these tumors were metastatic human melanoma by staining for human HMB45/MelanA (Fig. 5G) . Thus, the CDX had similar metastatic tropism in mice and the patient, and the cancer cells crossed the blood-brain barrier in both hosts. Copy number aberration (CNA) analysis revealed clear overlap of gains and losses in the patient's tumor and CDX (Fig. 6A) , and WES and RNAseq revealed extensive concordance of SNVs (Fig. 6B-C) . Notably, coincident with the patient's lack of response to dabrafenib, the CDX also failed to respond to this drug, showing only a 2-week delay in growth (Fig. 6D) .
We also developed a CDX from patient 11, who presented extensive metastasis in retrocrural lymph nodes and acute bowel obstruction. A BRAF V600E mutation was confirmed and the patient commenced vemurafenib, but was switched to dabrafenib due to skin toxicity (Fig. 6E) . The CDX from this patient, established at week 2, developed in ~2.5 months (F1 CDX), had a doubling time of ~10 days ( (Fig. 6G) . Moreover, following excision of the primary tumor, we observed widespread macroscopic disease in the mouse hosts (Fig. 6H) and coincident with the patient's short response to vemurafenib and dabrafenib, the CDX presented a short-lived response to PLX4720 (Fig. 6I) . Thus, we describe the development of melanoma CDXs, a new tool to study melanoma biology in patients with advanced stage disease, and for monitoring and predicting patient responses to therapy when tumors are inaccessible.
Research. 
DISCUSSION
There have been enormous advances in the management of melanoma over the past 5 years. New targeted and immunotherapies have improved progressionfree and overall survival in this disease, and in some cases led to cures. However, resistance emerges in the majority of patients on targeted therapies and not all patients respond to immunotherapies, so it is clinically challenging to select patients for these different modalities, to determine when to switch between modalities and to select second-line therapies for patients who fail to respond or who relapse. Here we describe systematic analysis of patient samples to improve the personalization of targeted and immunotherapies. We argue that no single approach allows refinement of care in all patients and that integration of data from a platform of technologies that interrogates different aspects of tumor biology is needed to select the most appropriate treatment for an individual patient. Clearly, these analyses need to be conducted in a timely manner so that treatment can be refined to ensure the best possible outcome.
It has been shown that ctDNA is a reliable, inexpensive and minimally invasive technique that allows assessment of response to therapy in breast and colorectal cancer (21, 36-38). This technology was previously explored in a small number of melanoma patients (39-41), primarily through application of mutationspecific droplet digital PCR assays. We extend those studies by establishing that next generation sequencing of ctDNA can be used as a routine clinical tool to monitor patient responses to treatment, but also to reveal mechanisms of resistance even in the absence of prior knowledge of the underlying molecular processes. We showed that longitudinal monitoring of BRAF and NRAS driver mutations could be used to prospectively follow patient responses to targeted therapy and 
VAF will provide an early warning of progression and the NRAS analysis will reveal mechanisms of resistance in approximately 30% of patients (32). In particular, this technique could be used to prioritize patients for scans so that disease progression can be confirmed early and patient care adjusted at the earliest opportunity. Over and above the benefits for individual patients, the use of ctDNA should allow treatment selection to be more cost effective, allowing more timely and accurate decision making on when to start or stop treatment with these very expensive drugs.
We show that PDX technologies can complement ctDNA analysis to optimize 
provide a foundation for patient stratification with this combination, validating the clinical relevance of our approach. Moreover, the approach is particularly relevant for umbrella and basket trials, where pre-clinical evaluation of drug efficiency or combinations in individual patient tumors could assist optimization of patient benefit and cost. We also show that this technology may assist in decisions about when to treat beyond relapse for some patients. Some of the limitations of the approach are access to new agents to test in PDX models, or to administer to the patients, but linking drugs to real time PDX data clearly has the potential to improve patient care and outcomes. We strongly advocate that PDXs are established as early as possible during patient care to allow as much time as possible for these studies to be conducted.
It is difficult to apply PDX technology to patients with very advanced disease who have exhausted conventional treatment options, as carrying out a biopsy solely to access fresh tumor for investigational techniques may not be considered to be in their best interest. Thus, while it is important to study late-stage disease biology, samples are difficult to obtain. We show that this limitation can be overcome in some patients by CDX techniques. We establish a proof-of-principle for this approach in melanoma and show that the CDXs resemble patient tumors and response to therapies. Our data establish that melanoma CTCs are tumorigenic and that they have similar tropism to the patient's own tumors. Because it is not currently possible to reliably quantify CTCs in melanoma, we cannot correlate CTC count to successful establishment of CDXs, but we note that in all seven cases where CDXs were established, the patients had widespread, late-stage disease, suggesting that this approach is more successful in patients with high disease burden. Thus, we establish that CDX technology is feasible in melanoma and this approach is 
particularly important when patient tumors are inaccessible or difficult to biopsy.
Clearly this technology provides an opportunity to study late-stage disease.
In summary, we describe integration of WES, ctDNA analysis, PDX and CDX technologies as a powerful platform to optimize clinical management of melanoma patients. We emphasize that it is not feasible to use all of these approaches in all patients but nevertheless careful selection of relevant components can be used to improve individual patient care. PDXs did not grow for ~30% of patients and the take-rate for CDXs was considerably lower, but the ctDNA still revealed responses to treatment and provided early warning of relapse in most patients. Moreover, WES or targeted sequencing of ctDNA provided insight into mechanisms of resistance in many patients. Our aim was to develop a pipeline to improve patient care and for at least one patient we obtained a treatment that was not otherwise available. This shows the power of our approach and we are now further refining our platform to enable us to optimize care for the majority of patients. (Table S2) . PCR products were gel purified using QIAquick 
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Q61R VAF (red), NRAS Q61K VAF (pink) and serum LDH (black) in patient 7.
LDH >550 IU/L = elevated LDH< 550 IU/L= normal; RT, Radiotherapy; SC, subcutaneous; D, dabrafenib; Vem, vemurafenib; LN, lymph node. 
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